About: Zanolimumab

An Entity of Type: monoclonal antibody, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org:8891

Zanolimumab (expected trade name HuMax-CD4) is a human monoclonal antibody and an immunosuppressive drug. It was developed with the goal of treatment of rheumatoid arthritis, psoriasis, melanoma, cutaneous and peripheral T-cell lymphoma. Development of the drug was ultimately discontinued with termination of all trials.

Property	Value
dbo:abstract	Zanolimumab (expected trade name HuMax-CD4) is a human monoclonal antibody and an immunosuppressive drug. It was developed with the goal of treatment of rheumatoid arthritis, psoriasis, melanoma, cutaneous and peripheral T-cell lymphoma. Development of the drug was ultimately discontinued with termination of all trials. (en)
dbo:casNumber	652153-01-0
dbo:fdaUniiCode	HG3L8885M0
dbo:kegg	D06356
dbo:wikiPageID	9132607 (xsd:integer)
dbo:wikiPageLength	3223 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID	1105545285 (xsd:integer)
dbo:wikiPageWikiLink	dbr:Psoriasis dbr:Human dbr:Rheumatoid_arthritis dbr:Melanoma dbr:Monoclonal_antibody dbr:T-cell_lymphoma dbc:Monoclonal_antibodies dbr:CD4 dbr:Immunosuppressive_drug
dbp:atcPrefix	none (en)
dbp:casNumber	652153 (xsd:integer)
dbp:chemspiderid	none (en)
dbp:kegg	D06356 (en)
dbp:mabType	mab (en)
dbp:molecularWeight	147 (xsd:integer)
dbp:source	u (en)
dbp:target	dbr:CD4
dbp:type	mab (en)
dbp:unii	HG3L8885M0 (en)
dbp:verifiedfields	changed (en)
dbp:verifiedrevid	470635574 (xsd:integer)
dbp:watchedfields	changed (en)
dbp:wikiPageUsesTemplate	dbt:Antineoplastic-drug-stub dbt:Drugbox dbt:Short_description dbt:Cascite dbt:Chemspidercite dbt:Drugbankcite dbt:Fdacite dbt:Keggcite dbt:Monoclonals_for_immune_system dbt:Immunosuppressants dbt:Monoclonal-antibody-stub
dcterms:subject	dbc:Monoclonal_antibodies
gold:hypernym	dbr:Antibody
rdf:type	owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:MonoclonalAntibody yago:WikicatMonoclonalAntibodies yago:Abstraction100002137 yago:Antibody115027189 yago:Chemical114806838 yago:Compound114818238 yago:Macromolecule114944888 yago:Material114580897 yago:Matter100020827 yago:Molecule114682133 yago:MonoclonalAntibody115029781 yago:OrganicCompound114727670 yago:Part113809207 yago:PhysicalEntity100001930 yago:Protein114728724 yago:Relation100031921 dbo:Drug yago:Substance100019613 yago:Thing100002452 yago:Unit109465459 umbel-rc:DrugProduct
rdfs:comment	Zanolimumab (expected trade name HuMax-CD4) is a human monoclonal antibody and an immunosuppressive drug. It was developed with the goal of treatment of rheumatoid arthritis, psoriasis, melanoma, cutaneous and peripheral T-cell lymphoma. Development of the drug was ultimately discontinued with termination of all trials. (en)
rdfs:label	Zanolimumab (en)
owl:sameAs	freebase:Zanolimumab yago-res:Zanolimumab wikidata:Zanolimumab dbpedia-fa:Zanolimumab dbpedia-vi:Zanolimumab https://global.dbpedia.org/id/4xJMb dbr:Zanolimumab
prov:wasDerivedFrom	wikipedia-en:Zanolimumab?oldid=1105545285&ns=0
foaf:isPrimaryTopicOf	wikipedia-en:Zanolimumab
is dbo:wikiPageRedirects of	dbr:HuMax-CD4
is dbo:wikiPageWikiLink of	dbr:HuMax-CD4 dbr:HuMax dbr:List_of_therapeutic_monoclonal_antibodies dbr:List_of_drugs:_Hf–Hz dbr:List_of_drugs:_Z
is foaf:primaryTopic of	wikipedia-en:Zanolimumab